US equities |
MU $1,097.39 ▲+3.03% NVDA $230.86 ▲+1.09% SNDK $1,787.69 ▲+2.75% INTC $120.00 ▼-0.19% AAPL $330.32 ▼-0.81% GOOGL $338.24 ▼-1.70% TSLA $354.11 ▼-0.20% AMD $615.73 ▲+0.65%
FinancialContent

Alkermes plc - Ordinary Shares (NQ:ALKS)

40.54 +0.02 (+0.05%)
Delayed Quote Updated: 4:00 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,626,369
Open 40.00
Bid (Size) 40.56 (100)
Ask (Size) 40.57 (100)
Prev. Close 40.52
Today's Range 39.99 - 41.41
52wk Range 27.00 - 55.67
Shares Outstanding 166,121,384
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
From Alkermes plc
Via Business Wire
News headline image
Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors
From Alkermes plc
Via Business Wire

Performance

YTD
+43.5%
+43.5%
1 Month
-14.1%
-14.1%
3 Month
-25.7%
-25.7%
6 Month
+16.4%
+16.4%
1 Year
+32.3%
+32.3%

More News

Read More
News headline image
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program
From Alkermes plc
Via Business Wire
Alkermes (NASDAQ:ALKS) Reports Quality Earnings Beat but Stock Falls on Lack of Guidance ↗
Via Chartmill
Topics Earnings
Alkermes plc (NASDAQ:ALKS) Reports Mixed Q1 Results, Beats Revenue Forecasts but Posts Wider Than Expected Loss ↗
Via Chartmill
Alkermes Plc (NASDAQ:ALKS) Shows Strong Technical Setup with High Breakout Potential ↗
Via Chartmill
News headline image
Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000 ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
From Alkermes plc
Via Business Wire
News headline image
Alkermes Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Alkermes plc Reports Second Quarter 2026 Financial Results
From Alkermes plc
Via Business Wire
News headline image
Alkermes to Report Second Quarter Financial Results on July 28, 2026
From Alkermes plc
Via Business Wire
News headline image
Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis
From Alkermes plc
Via Business Wire
News headline image
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
From Alkermes plc
Via Business Wire
News headline image
Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe
From Alkermes plc
Via Business Wire
News headline image
Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears ↗
Via MarketBeat
News headline image
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
From Alkermes plc
Via Business Wire
News headline image
Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
From Alkermes plc
Via Business Wire
News headline image
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting
From Alkermes plc
Via Business Wire
News headline image
Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences
From Alkermes plc
Via Business Wire
News headline image
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia
From Alkermes plc
Via Business Wire
News headline image
Alkermes (ALKS) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Alkermes plc Reports First Quarter 2026 Financial Results
From Alkermes plc
Via Business Wire
News headline image
Alkermes to Report First Quarter Financial Results on May 5, 2026
From Alkermes plc
Via Business Wire
News headline image
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
From Alkermes plc
Via Business Wire
News headline image
Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry
From Alkermes plc
Via Business Wire

Frequently Asked Questions

Is Alkermes plc - Ordinary Shares publicly traded?
Yes, Alkermes plc - Ordinary Shares is publicly traded.
What exchange does Alkermes plc - Ordinary Shares trade on?
Alkermes plc - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Alkermes plc - Ordinary Shares?
The ticker symbol for Alkermes plc - Ordinary Shares is ALKS on the Nasdaq Stock Market
What is the current price of Alkermes plc - Ordinary Shares?
The current price of Alkermes plc - Ordinary Shares is 40.54
When was Alkermes plc - Ordinary Shares last traded?
The last trade of Alkermes plc - Ordinary Shares was at 10/01/26 04:00 PM ET
What is the market capitalization of Alkermes plc - Ordinary Shares?
The market capitalization of Alkermes plc - Ordinary Shares is 6.73B
How many shares of Alkermes plc - Ordinary Shares are outstanding?
Alkermes plc - Ordinary Shares has 7B shares outstanding.